Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Construction in Progress (2017 - 2020)

Historic Construction in Progress for Champions Oncology (CSBR) over the last 4 years, with Q4 2020 value amounting to $441000.0.

  • Champions Oncology's Construction in Progress changed N/A to $441000.0 in Q4 2020 from the same period last year, while for Oct 2020 it was $441000.0, marking a year-over-year change of. This contributed to the annual value of $554000.0 for FY2020, which is 336250.0% up from last year.
  • According to the latest figures from Q4 2020, Champions Oncology's Construction in Progress is $441000.0.
  • Champions Oncology's Construction in Progress' 5-year high stood at $619000.0 during Q3 2019, with a 5-year trough of $15000.0 in Q2 2018.
  • For the 4-year period, Champions Oncology's Construction in Progress averaged around $196076.9, with its median value being $58000.0 (2018).
  • Its Construction in Progress has fluctuated over the past 5 years, first tumbled by 9682.2% in 2018, then soared by 336250.0% in 2020.
  • Quarter analysis of 4 years shows Champions Oncology's Construction in Progress stood at $19000.0 in 2017, then skyrocketed by 31.58% to $25000.0 in 2018, then soared by 2376.0% to $619000.0 in 2019, then dropped by 28.76% to $441000.0 in 2020.
  • Its Construction in Progress was $441000.0 in Q4 2020, compared to $114000.0 in Q3 2020 and $554000.0 in Q2 2020.